Search results for "Granulomatosis"

showing 4 items of 34 documents

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission in…

2019

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its con…

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drugLa Presse Médicale
researchProduct

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

THU0045 IL-25/IL-17RB AXIS IS ACTIVATED AND ASSOCIATED WITH ILC2 EXPANSION IN GRANULOMATOSIS WITH POLYANGIITIS (GPA)

2019

Background: Pathogenesis of Granulomatosis with polyangiitis (GPA) is still unknown. However, it has been observed a skewing of circulating CD4+ T cells toward the Th17 and Th2 phenotype. The pro-inflammatory cytokine interleukin 25 (IL-25) is a member of IL-17 cytokine family associated to the Th2 immune phenotype. Through the receptor IL17RB, IL-25 further sustains the Th2-type immune response and elicits the expansion of the type 2 innate lymphoid cells (ILC2) and M2 macrophages. A pathogenic role of the innate lymphoid cells in GPA has been recently demonstrated; however, the relevance of IL-25 in this condition remains unexplored. Objectives: Aim of the study was to evaluate the expres…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentInnate lymphoid cellConsensus conferenceGATA3medicine.diseaseGastroenterologyPathogenesisImmune systemCytokineInternal medicineMedicineRituximabbusinessGranulomatosis with polyangiitismedicine.drugPoster Presentations
researchProduct

Orofacial granulomatosis: a rare case report with review of literature

2010

The term orofacial granulomatosis (OFG) is a descriptive term used for granulomatous disorders affecting the face and oral cavity, which can occur for a variety of reasons resulting in significant morbidity. It is characterised by persistent swelling that may involve one or both the lips and /or recurrent ulcers and a variety of other orofacial features. Medical history is very important in the diagnosis of OFG as medical condition like Crohn’s disease can also present an extra intestinal manifestation of OFG. Exclusion of other entities like sarcoidosis, mycobacterial infections, foreign body reactions and biopsy helps to establish a correct diagnosis. Herein we report a case of OFG in a 5…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryOdontologíaDisease:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologyCiencias de la saludSurgeryRare caseFemale patientBiopsyUNESCO::CIENCIAS MÉDICASmedicineMedical historySarcoidosisOrofacial granulomatosisForeign bodybusinessGeneral Dentistry
researchProduct